The Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) Administrative Core includes both Senior Leadership and central Administration, and oversees all strategic, operational, and financial aspects of the WFBCCC. The two teams work in tandem to deliver the goals of the Center, thereby meeting the mission of improving the lives of people in the multi-state Piedmont and southern Appalachian region. The Senior Leadership team establishes the vision for the WFBCCC to address the strategic priorities and operational aspects of the Center, such as Program goals, transdisciplinary and translational research needs and assessment, strategic recruitment, pilot projects, external speakers, and patient accruals to clinical trials. The Deputy Director and the Associate Directors for Basic Sciences, Population Sciences, Clinical Research, Cancer Health Equity, Shared Resources, Informatics, and Administration attend these meetings. All but one of these senior leaders is newly-appointed to these roles, in response to feedback from the External Advisory Board and the 2011 Summary Statement to expand the Senior Leadership ranks in further support of the Director. Under Dr. Pasche's leadership, the WFBCCC is stronger because of this structure, and these leaders have helped create the new initiatives described in this application and brought a fresh perspective to the WFBCCC's strategic vision. The Administrative team facilitates the implementation of the vision set by WFBCCC Senior Leadership and fosters an environment of collaboration and interaction with its membership. It consists of 13 FTEs and oversees all aspects of the Center's operations, including Shared Resource personnel and process management, informatics infrastructure support and expertise, financial leadership and management, faculty recruitment and space utilization, pilot award programs, Planning and Evaluation facilitation (internal and external advisory boards/committees and speakers), clinical research management, membership management and communication, cancer health equity and community outreach activities, and personnel support. The Administrative team is also responsible for all required CCSG reporting related to membership accomplishments (e.g. funding, publications, Shared Resource usage, and clinical trial accruals). The two groups are closely linked through frequent formal and informal meetings, allowing the WFBCCC Administrative team to be responsive to the direction set forth by the Senior Leadership.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wake Forest University Health Sciences
United States
Zip Code
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Haas, Karen M; Johnson, Kristen L; Phipps, James P et al. (2018) CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens. J Immunol 200:1671-1681
Suo, Xubin; Eldridge, Brittany N; Zhang, Han et al. (2018) P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes. ACS Appl Mater Interfaces 10:33464-33473
Widner, D Brooke; Park, Sun H; Eber, Matthew R et al. (2018) Interactions Between Disseminated Tumor Cells and Bone Marrow Stromal Cells Regulate Tumor Dormancy. Curr Osteoporos Rep 16:596-602
Liu, Liang; Ruiz, Jimmy; O'Neill, Stacey S et al. (2018) Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer 17:81
Sirkisoon, Sherona R; Carpenter, Richard L; Rimkus, Tadas et al. (2018) Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene 37:2502-2514
Goyal, Amrita; Carter, Joi B; Pashtan, Itai et al. (2018) Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study. J Am Acad Dermatol 78:408-410
Su, Weijun; Hong, Lixin; Xu, Xin et al. (2018) miR-30 disrupts senescence and promotes cancer by targeting both p16INK4A and DNA damage pathways. Oncogene 37:5618-5632
Miller Jr, David P; Denizard-Thompson, Nancy; Weaver, Kathryn E et al. (2018) Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial. Ann Intern Med 168:550-557
Rimkus, Tadas K; Carpenter, Richard L; Sirkisoon, Sherona et al. (2018) Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer Res 78:2589-2600

Showing the most recent 10 out of 548 publications